ReviewMikrochimica acta2025
Nanomaterial-based biosensors for cancer diagnosis: trends and innovations (2022-2025).
Review in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Single-Atom and Subnanocluster Platforms for Next-Generation Clinical Practice: A Bench-to-Bedside Approach.Chemistry, an Asian journal · 2026Review
- Cardio Protective Role of Graphene-based FeCell biochemistry and biophysics · 2026Article
- Real-Time and Spatially Resolved Epigenetic Dynamics Tracking Beyond DNA Methylation via Live-Cell Epigenetic Sensors in 3D Systems.Biosensors · 2026Review
- Bibliometric and visualized analysis of nanomedicine research trends for gastric cancer during the early 21st century.Discover nano · 2026Review
- Quantum dot enhanced photonic biosensors for single cell analysis from synthesis to clinical application.Discover nano · 2026Review
- Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.Journal of clinical and translational hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a significant global health concern, with its prevalence continuing to rise steadily. Early detection is vital for improving treatment outcomes and survival rates by enabling timely intervention and effective disease management. Biosensors have emerged as crucial tools in cancer diagnosis, offering high sensitivity, selectivity, and rapid detection of biomarkers. Among them, nanomaterial-based biosensors have gained significant attention due to their unique properties, including enhanced biocompatibility, stability, and large surface area for biomolecule interaction. These sensors utilize materials like metal nanoparticles, quantum dots, and other nanomaterials, which amplify signals and improve detection limits, making them highly effective for identifying cancer at its earliest stages. Their adaptability and potential for multiplexed detection further highlight their value in advancing cancer diagnostics and treatment strategies. This review explores recent advancements in nanomaterial-based biosensors for detecting cancer-related biomarkers, highlighting their critical role in early diagnosis. Key biomarkers covered include CA15-3, GPC3, Cyfra 21-1, CA-125, CRT, PDGF, PSA, miRNA-122, Anti-P53, YES1, CEA, PSMA, miR-141, c-Met protein, miR-106b, HER-2, Pax-5a, mSEPT9, and miR-21. By focusing on studies conducted between 2022 and 2025, the review addresses emerging applications and future prospects of these biosensors.
Indexed as
Identifiers
40465004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.